5 Best Shipping Stocks For 2014

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Company

June 21

Weekly Loss

Ebix (NASDAQ: EBIX  )

$9.52

51%

Eagle Bulk Shipping (NASDAQ: EGLE  )

$3.25

20%

Fortuna Silver Mines (NYSE: FSM  )

$3.02

16%

Celldex (NASDAQ: CLDX  )

$14.06

12%

Hovnanian (NYSE: HOV  )

Best European Stocks To Watch Right Now: Express-1 Expedited Solutions Inc.(XPO)

XPO Logistics, Inc. provides third-party logistics services using a network of relationships with ground, sea, and air carriers in the United States, Mexico, and Canada. It operates in three segments: Express-1, Concert Group Logistics, and Bounce Logistics. The Express-1 segment offers ground expedited surface transportation services for freight. It operates a fleet ranging from cargo vans to semi tractor trailer units. The Concert Group Logistics segment provides domestic and international freight forwarding services through a network of independently owned stations. Its domestic freight forwarding services include air charter, expedites, and time sensitive services, as well as cost sensitive services comprising deferred delivery, less than truckload, and full truck load services; and international freight forwarding services consist of on-board courier and air charters, time sensitive services, less-than-container and full-container-loads, and vessel charters. This segm ent also offers documentation on international shipments, customs clearance and banking, trade show shipment management, time definite and customized product distributions, reverse logistics and on site asset recovery projects, installation coordination, freight optimization, and diversity compliance support services. The Bounce Logistics segment provides premium freight brokerage services for truckload shipments. The company serves approximately 4,000 retail, commercial, manufacturing, and industrial customers through 6 U.S. operations centers and 22 agent locations. It offers its services to the automotive manufacturing, automotive components and supplies, commercial printing, durable goods manufacturing, pharmaceuticals, food and consumer products, and high tech sectors. The company was formerly known as Express-1 Expedited Solutions, Inc. and changed its name to XPO Logistics, Inc. in September 2011. XPO Logistics, Inc. was founded in 1989 and is based in Buchanan, Michi gan.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  XPO Logistics (NYSE: XPO) shot up 7.06 percent to $30.01 after the company announced its plans to acquire Pacer International (NASDAQ: PACR) in a deal valued at $335 million.

• [By Travis Hoium]

  What: Shares of XPO Logistics (NYSE: XPO  ) jumped 13% today after announcing an acquisition.

  So what: The company will pay $365 million for logistics provider 3PD, consisting of $357 million in cash an $8 million in XPO restricted stock. Is will use its own cash and borrow $195 million from Credit Suisse Group for the remainder of the purchase. �

• [By Vera Yuan]

  We initiated a new position in Aircastle Ltd. (AYR), an aircraft leasing company with a flexible business model and a rational capital allocation philosophy. We took advantage of an opportunity to purchase shares in the heavily capitalized Georgia bank State Bank Financial Corp. (STBZ) as the depressed stock price reflected investors��lack of patience with a slower than expected pace of capital deployment. We like State Bank�� management team led by Georgia banker Joe Evans. This management team has experience successfully building and selling other Georgia banks. We also received shares of transportation infrastructure company XPO Logistics, Inc. (XPO) as a result of its acquisition of holding Pacer International, Inc.

5 Best Shipping Stocks For 2014: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell�� cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, its plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitro experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors' Opinion:

• [By Maxx Chatsko]

  Industrial biotech isn't the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil's Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix's first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product's commercialization and the adoption of Protalix's novel plant cell-based expression system for therapeutic proteins.

• [By Keith Speights]

  Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a "broad array of strategic alternatives."

5 Best Shipping Stocks For 2014: LCY Chemical Corp (1704.TW)

LCY Chemical Corporation is principally engaged in the manufacture and distribution of polypropylene (PP), solvents and other chemical products. The Company provides methanol products, including methanol, formaldehyde, paraformaldehyde and dimethyl ether, among others; solvents, including ethyl acetate, isopropyl alcohol and methyl isobutyl ketone, as well as electronic chemical products, PP related products, thermoplastic rubber and liquefied petroleum gas (LPG). Its products are applied in the manufacture of resins, agricultural pesticides, catalysts, medicines, paintings, inks, artificial leather products, shoes, industrial products, electronic components, toys and electrical appliances, among others. On June 23, 2014, it acquired a certain shares of TECHNOLOGY CORP. After that, it holds 86.65% stake of LCY TECHNOLOGY CORP. Advisors' Opinion:

• [By Anna Prior]

  Kraton Performance Polymers Inc.'s(KRA) board is no longer pushing for the company’s stockholders to approve its plans to combine with LCY Chemical Corp.'s(1704.TW) styrenic block copolymer operations.

5 Best Shipping Stocks For 2014: Kadant Inc (KAI)

Kadant Inc., incorporated in November 1991, is a supplier of equipment used in the global papermaking and paper recycling industries and a manufacturer of granules made from papermaking byproducts. Through its Papermaking Systems segment, the Company develops, manufactures and markets a range of equipment and products for the global papermaking, paper recycling, and process industries. Through its Fiber-based Products business, the Company manufacture and sell granules derived from pulp fiber for use as carriers for agricultural, home lawn and garden, and professional lawn, turf and ornamental applications, as well as for oil and grease absorption. Its Papermaking Systems segment consists of product lines, such as stock-preparation, fluid-handling, doctoring and water-management. On May 27, 2011, its subsidiary, Kadant Johnson Europe B.V., acquired all the interests in m-clean papertech holding AB. In April 2013, it completed the acquisition of Companhia Brasileira de Tecnologia Industrial (CBTI).

The Company�� customer base includes major global paper manufacturers and with its equipment found in most of pulp and paper mills. The Company manufactures its products in nine countries in Europe, North and South America and Asia. It develop, manufacture and market complete custom-engineered systems and equipment, as well as standard individual components, for pulping, de-inking, screening, cleaning, and refining recycled and virgin fibers for preparation for entry into the paper machine. Its principal stock-preparation products include recycling and approach flow systems and Virgin pulping process equipment.

The Company develop, manufacture and market rotary joints, precision unions, steam and condensate systems, components, and controls used primarily in the dryer section of the papermaking process and during the production of corrugated boxboard, metals, plastics, rubber, textiles, chemicals and food. Its principal fluid-handling systems include rotary joints, siphons, turbul! ator bars, and engineered steam and condensate systems. Its mechanical devices, used with rotating shafts, allow the transfer of pressurized fluid from a stationary source into and out of rotating machinery for heating, cooling, or the transfer of fluid power. Its devices, installed primarily inside the rotating cylinders of paper machines, are used to remove condensate from the drying cylinders through rotary joints located on either end of the cylinder. Its steel or stainless steel axial bars, installed on the inside of cylinders, are used to induce turbulence in the condensate layer to improve the uniformity and rate of heat transfer through the cylinders. Its steam systems control the flow of steam from the boiler to the paper drying cylinders, collect condensed steam, and return it to the boiler to improve energy efficiency during the paper drying process.

The Company develop, manufacture and market a range of doctoring systems and related consumables that continuously clean rolls to keep paper machines running efficiently; doctor blades made of a variety of materials to perform functions, including cleaning, creping, web removal, flaking, and the application of coatings, and profiling systems that control moisture, Web curl, and gloss during paper converting. Its principal doctoring products include doctor systems and holders, profiling systems and doctor blades. Its doctor systems clean papermaking rolls to maintain the operation of paper machines and other equipment by placing a blade against the roll at a constant and uniform pressure. A doctor system consists of the structure supporting the blade and the blade holder. It offers profiling systems that control moisture, Web curl, and gloss during paper converting. It manufacture doctor and scraper blades made of a variety of materials, including metal, bi-metal, or synthetic materials that perform a variety of functions, including cleaning, creping, Web removal, flaking and the application of coatings.

The Company devel! ops, manu! facture and markets water-management systems and equipment used to continuously clean paper machine fabrics and rolls, drain water from pulp mixtures, form the sheet or Web, and filter the process water for reuse. Its principal water-management systems include shower and fabric-conditioning systems, formation systems, and water-filtration systems. Its shower and fabric-conditioning systems assist in the removal of contaminants that collect on paper machine fabrics used to convey the paper Web through the forming, pressing and drying sections of the paper machine. A typical paper machine has between 3 and 12 fabrics. It supplies structures that drain, purify, and recycle process water from the pulp mixture during paper sheet and Web formation. It offer a variety of filtration systems and strainers that remove contaminants from process water before reuse and recover reusable fiber for recycling back into the pulp mixture.

The Company competes with Voith Paper GmbH, Metso Corporation, Maschinenfabrik Andritz AG, Deublin Company, Barco Company, Christian Maier GmbH & Co. KG, Duff-Norton Company, Joh. Clouth GmbH & Co. KG, Bonetti, S.p.A., Metso Corporation and IBS-Paper Performance Group.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Kadant (NYSE: KAI  ) , whose recent revenue and earnings are plotted below.